# Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer

> **NCT01064375** · PHASE1,PHASE2 · COMPLETED · sponsor: **Maria Liljefors** · enrollment: 16 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)
- **DEVICE:** Derma Vax (electroporation device)
- **BIOLOGICAL:** GM-CSF
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01064375
- **Lead sponsor:** Maria Liljefors
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-03
- **Final completion:** 2016-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-08-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064375, "Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01064375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*